These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35117)

  • 1. Improvement in tardive dyskinesia after muscimol therapy.
    Tamminga CA; Crayton JW; Chase TN
    Arch Gen Psychiatry; 1979 May; 36(5):595-8. PubMed ID: 35117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic studies of tardive dyskinesia.
    Chase TN; Tamminga CA
    Adv Biochem Psychopharmacol; 1980; 24():457-61. PubMed ID: 7405673
    [No Abstract]   [Full Text] [Related]  

  • 3. Tardive dyskinesia: a role for the endogenous opioid system.
    Sandyk R
    Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia.
    Cassady SL; Thaker GK; Moran M; Birt A; Tamminga CA
    Biol Psychiatry; 1992 Aug; 32(4):302-11. PubMed ID: 1358231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
    Berger PA; Rexroth K
    Schizophr Bull; 1980; 6(1):102-16. PubMed ID: 6102788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GABA system: clinical research and treatment of tardive dyskinesia.
    Thaker GK; Hare TA; Tamminga CA
    Mod Probl Pharmacopsychiatry; 1983; 21():155-67. PubMed ID: 6419061
    [No Abstract]   [Full Text] [Related]  

  • 9. Tardive dyskinesia: pathophysiology and animal models.
    Casey DE
    J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on tardive dyskinesia.
    Simpson GM; Pi EH; Sramek JJ
    Hosp Community Psychiatry; 1986 Apr; 37(4):362-9. PubMed ID: 2870977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Soares KV; McGrath JJ; Deeks JJ
    Cochrane Database Syst Rev; 2001; (2):CD000203. PubMed ID: 11405955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Physiopathology and curative treatment of tardive dyskinesia].
    Wolf MA; Gautier J
    Encephale; 1987; 13(5):301-8. PubMed ID: 2892663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
    Arushanian EB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(2):269-77. PubMed ID: 2858951
    [No Abstract]   [Full Text] [Related]  

  • 14. [Occurrence of tardive extrapyramidal symptoms in schizophrenic patients undergoing prolonged neuroleptic treatment].
    Rybakowski J; Jaracz J; Lis B; Milewska G; Lezańska M
    Psychiatr Pol; 1979; 13(5):479-85. PubMed ID: 42096
    [No Abstract]   [Full Text] [Related]  

  • 15. GABA dysfunction in the pathophysiology of tardive dyskinesia.
    Tamminga CA; Thaker GK; Chase TN
    Psychopharmacology Suppl; 1985; 2():122-7. PubMed ID: 2987903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Soares KV; McGrath JJ; Deeks JJ
    Cochrane Database Syst Rev; 2000; (2):CD000203. PubMed ID: 10796320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia.
    Morselli PL; Fournier V; Bossi L; Musch B
    Psychopharmacology Suppl; 1985; 2():128-36. PubMed ID: 2860656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist.
    Korsgaard S; Casey DE; Gerlach J; Hetmar O; Kaldan B; Mikkelsen LB
    Arch Gen Psychiatry; 1982 Sep; 39(9):1017-21. PubMed ID: 6126170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment.
    Thaker GK; Tamminga CA; Alphs LD; Lafferman J; Ferraro TN; Hare TA
    Arch Gen Psychiatry; 1987 Jun; 44(6):522-9. PubMed ID: 3034188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.